PL2799089T3 - Process for preparing a pharmaceutical formulation of contrast agents - Google Patents

Process for preparing a pharmaceutical formulation of contrast agents

Info

Publication number
PL2799089T3
PL2799089T3 PL14165006T PL14165006T PL2799089T3 PL 2799089 T3 PL2799089 T3 PL 2799089T3 PL 14165006 T PL14165006 T PL 14165006T PL 14165006 T PL14165006 T PL 14165006T PL 2799089 T3 PL2799089 T3 PL 2799089T3
Authority
PL
Poland
Prior art keywords
preparing
pharmaceutical formulation
contrast agents
agents
contrast
Prior art date
Application number
PL14165006T
Other languages
English (en)
Inventor
Dominique Meyer
Claire Corot
Marc Port
Vincent Barbotin
Bruno Bonnemain
Original Assignee
Guerbet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40955314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2799089(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0851055A external-priority patent/FR2927539B1/fr
Application filed by Guerbet filed Critical Guerbet
Publication of PL2799089T3 publication Critical patent/PL2799089T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL14165006T 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents PL2799089T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0851055A FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
EP08154745 2008-04-17
US12/155,997 US20090208421A1 (en) 2008-02-19 2008-06-12 Process for preparing a pharmaceutical formulation of contrast agents
EP14165006.9A EP2799089B9 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents

Publications (1)

Publication Number Publication Date
PL2799089T3 true PL2799089T3 (pl) 2017-08-31

Family

ID=40955314

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14165008.5T PL2799090T5 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych
PL14165006T PL2799089T3 (pl) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
PL09712403T PL2242515T3 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14165008.5T PL2799090T5 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09712403T PL2242515T3 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych

Country Status (17)

Country Link
US (6) US20090208421A1 (pl)
EP (6) EP2799089B9 (pl)
JP (3) JP5469615B2 (pl)
KR (1) KR101063060B1 (pl)
CN (1) CN101977633B (pl)
BR (1) BRPI0908221B1 (pl)
CA (1) CA2714118C (pl)
CY (2) CY1115259T1 (pl)
DE (1) DE202008010019U1 (pl)
DK (3) DK2799090T4 (pl)
ES (3) ES2597782T3 (pl)
HR (2) HRP20140537T1 (pl)
HU (2) HUE030219T2 (pl)
LT (2) LT2799089T (pl)
PL (3) PL2799090T5 (pl)
PT (3) PT2799090T (pl)
WO (1) WO2009103744A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) * 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) * 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
DK2941233T3 (da) * 2013-01-07 2020-10-19 Univ Pennsylvania Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
EP2786768A1 (en) * 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
HRP20170874T4 (hr) 2013-04-26 2022-09-02 Guerbet Formulacija kontrastnog medija i odgovarajući postupak dobivanja
KR101466602B1 (ko) * 2013-05-31 2014-12-01 동국제약 주식회사 메글루민 가도테레이트를 포함하는 조영제 조성물의 제조방법
AT516104B1 (de) * 2014-07-31 2016-08-15 Sanochemia Pharmazeutika Ag Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung
KR101646211B1 (ko) * 2014-11-12 2016-08-05 (주)디아이테크 자기공명영상용 조영제의 제조방법
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
GB201421162D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
GB201421163D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Formulations of metal complexes
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20170035461A1 (en) * 2015-08-03 2017-02-09 Jeffery Deal Reversible tattoo colorant and method
DE102015013939A1 (de) * 2015-09-15 2017-03-16 be imaging GmbH Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen
EP3183009B1 (en) * 2015-09-30 2023-08-09 Duke University Contrast agents for magnetic resonance imaging
KR101625656B1 (ko) * 2015-10-16 2016-05-30 최경석 자기공명영상용 조영제의 제조방법
EP3383441A1 (en) * 2015-11-30 2018-10-10 GE Healthcare AS Formulations comprising a combination of mri contrast agents
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
EP3315141B1 (de) * 2016-10-28 2020-10-21 B.E. Imaging GmbH Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
JP7258753B2 (ja) 2016-12-21 2023-04-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ Ｍｒｉイメージング剤として好適なテトラアザビシクロ大員環系マンガンキレート化合物
EP3562517A1 (en) * 2016-12-29 2019-11-06 Inventure, LLC Solvent-free gadolinium contrast agents
US20190269805A1 (en) * 2016-12-29 2019-09-05 Inventure, LLC Solvent-free gadolinium contrast agents
WO2018204869A1 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3638320A4 (en) 2017-05-05 2021-01-20 Centre for Probe Development and Commercialization IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
WO2019020662A1 (de) * 2017-07-27 2019-01-31 Sanochemia Pharmazeutika Ag Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen
FR3072281B1 (fr) * 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
US11110186B2 (en) 2017-12-20 2021-09-07 General Electric Company Anionic chelate compounds
AT521001B1 (de) 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
EP3883613A1 (en) * 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
JP2022517193A (ja) * 2019-01-03 2022-03-07 アイオンパス， インク． イオンビームイメージングのための組成物および試薬
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
AU2020291197A1 (en) * 2019-06-14 2022-01-27 Edinburgh Molecular Imaging Limited Compounds and methods of use
US20220370646A1 (en) * 2019-10-25 2022-11-24 Bracco Imaging S.P.A. Pharmaceutical compositions of gd-based contrast agents
GB201919073D0 (en) 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
TWI779284B (zh) * 2020-05-06 2022-10-01 商之器科技股份有限公司 用於影像資料標註的裝置
CN115916761B (zh) 2020-06-10 2025-08-12 贾斯特萨影象独资有限公司 利用高纯度四西坦(dota)制取钆特酸葡甲胺的方法及其在制备可注射盖仑制剂中的应用
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法
WO2025034668A1 (en) * 2023-08-04 2025-02-13 Inventure, LLC Lanthanide-based contrast agents having improved stability and methods for their production and purification
CN119612783B (zh) * 2024-12-23 2025-09-02 欣格瑞(山东)化学有限公司 一种硫酸钡锶除垢剂的制备方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4639365A (en) 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US5082649A (en) 1987-06-30 1992-01-21 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5049667A (en) 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
EP0367787B2 (en) 1987-06-30 1999-01-27 Mallinckrodt, Inc. (a Delaware corporation) Method for enhancing the safety of metal-ligand chelates as x-ray contrast agents
NZ230778A (en) 1988-09-27 1993-01-27 Salutar Inc Diagnostic imaging contrast medium comprising biscarbamoyl derivatives
JPH02173483A (ja) 1988-12-23 1990-07-04 Komatsu Ltd 高速流量制御弁
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US4967447A (en) 1989-09-25 1990-11-06 Romaine Jeffrey L Fish slicer and method of frying fish
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9000564D0 (en) 1990-01-10 1990-03-14 Dow Rheinmuenster Modified polyoxyethlene epoxy resin amphiphiles and stable aqueous epoxy dispersions thereof
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US7385041B2 (en) * 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
JPH07505886A (ja) * 1992-04-13 1995-06-29 ザ　ダウ　ケミカル　カンパニー マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
FR2736051B3 (fr) * 1995-06-29 1997-09-26 Guerbet Sa Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US7048907B2 (en) * 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
AU2003261398A1 (en) * 2002-08-06 2004-02-23 Epix Pharmaceuticals, Inc. Peptide aggregates
WO2007002109A2 (en) 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
JP2009530294A (ja) 2006-03-15 2009-08-27 マリンクロット インコーポレイテッド 置換芳香族部分を有するキレート化接合体およびその誘導体
WO2007121453A2 (en) 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents

Also Published As

Publication number Publication date
DE202008010019U1 (de) 2009-07-02
PL2242515T3 (pl) 2014-08-29
ES2593127T9 (es) 2017-05-08
US9636427B2 (en) 2017-05-02
EP2799090B9 (en) 2016-12-21
JP2014114306A (ja) 2014-06-26
HRP20161312T1 (hr) 2016-12-16
US9907866B2 (en) 2018-03-06
PT2799089T (pt) 2016-10-25
ES2593127T5 (es) 2020-09-25
DK2799090T5 (en) 2017-04-18
EP2799089B9 (en) 2017-09-06
LT2799089T (lt) 2016-11-10
US20130336898A1 (en) 2013-12-19
CY1115259T1 (el) 2017-01-04
US20090208421A1 (en) 2009-08-20
US20110129425A1 (en) 2011-06-02
EP3620179A1 (en) 2020-03-11
DK2799089T3 (en) 2016-11-21
CY1118985T1 (el) 2018-01-10
JP6422460B2 (ja) 2018-11-14
CA2714118C (en) 2017-03-28
EP2799090B1 (en) 2016-06-29
HRP20161312T2 (hr) 2018-01-26
BRPI0908221A2 (pt) 2018-03-20
DK2799090T4 (da) 2020-05-18
JP5985523B2 (ja) 2016-09-06
ES2477541T3 (es) 2014-07-17
BRPI0908221B1 (pt) 2021-07-13
EP3159014A1 (en) 2017-04-26
EP2799090A2 (en) 2014-11-05
LT2799090T (lt) 2016-10-10
HUE030219T2 (en) 2017-04-28
EP2799090A3 (en) 2015-01-14
EP2242515B9 (en) 2014-10-01
KR101063060B1 (ko) 2011-09-07
EP2799089A3 (en) 2015-03-04
JP2016117778A (ja) 2016-06-30
HRP20140537T1 (hr) 2014-07-18
PT2799090T (pt) 2016-09-28
PT2242515E (pt) 2014-07-11
US20160235867A1 (en) 2016-08-18
JP2011514334A (ja) 2011-05-06
EP2799089B1 (en) 2016-08-03
PL2799090T5 (pl) 2020-07-13
EP2799089A2 (en) 2014-11-05
WO2009103744A2 (en) 2009-08-27
PL2799090T3 (pl) 2017-08-31
KR20100133976A (ko) 2010-12-22
WO2009103744A3 (en) 2009-12-17
HUE031091T2 (en) 2017-06-28
US9655983B2 (en) 2017-05-23
EP2242515A2 (en) 2010-10-27
ES2597782T3 (es) 2017-01-23
ES2593127T3 (es) 2016-12-05
EP2799090B2 (en) 2020-03-04
DK2242515T3 (da) 2014-07-07
CN101977633B (zh) 2012-08-29
DK2799090T3 (en) 2016-10-03
US20170189563A1 (en) 2017-07-06
JP5469615B2 (ja) 2014-04-16
CA2714118A1 (en) 2009-08-27
EP2591807A1 (en) 2013-05-15
EP2242515B1 (en) 2014-04-02
CN101977633A (zh) 2011-02-16
US20160235868A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
IL237642A (en) METHOD FOR PREPARING PHARMACEUTICAL MATERIALS
AP3050A (en) New Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions comprising them
IL211701A0 (en) Process for the preparation of bendamustine
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
ZA201200719B (en) Pharmaceutical formulation
IL207526A0 (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
ZA201100231B (en) Process for preparing a mixture of lactide derivatives
IL211053A0 (en) A process for preparation of insulin compounds
IL207183A0 (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
IL213354A0 (en) Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
ZA201101645B (en) Process for prodcution of vaccines
HU1000444D0 (en) Process for the preparation of a pharmaceutical active ingredient
IL217393A0 (en) Process for the preparation of a iodinating agent
GB2444572B (en) A process for the preparation of a stable anhydrous anthelmintic formulation
PL2276762T3 (pl) Sposób wytwarzania jałowego doripenemu
EP2250178A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF TRIAZOL-BENZODIAZEPINE DERIVATIVES
HU0800239D0 (en) Process for preparation of cyclohexanol derivatives
GB0805292D0 (en) Pharmaceutical formulation
GB0805953D0 (en) Process for the manufacture of a pharmaceutical product
SI2321312T1 (sl) Postopek za pripravo paliperidona
IL193470A0 (en) Process for preparing of 2-alkyl-3-aryl-prop-2- ene-1-ols
GB0812609D0 (en) Process for the preparation of deoxynojirimycin
IL215143A0 (en) Process for the preparation of alogliptin
GB0906003D0 (en) Oral drug formulation